SuperworthQuidelOrtho EPS QDEL
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 28, 2026
- −$15.41
- Latest quarter, Q2 FY26
- −$1.36
- Fiscal year 2025
- −$16.66
QuidelOrtho's earnings per share was −$15.41 over the twelve months to Jun 28, 2026.
In its latest quarter, Q2 FY26, it was −$1.36.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$16.66 | n/a |
| FY2024 | −$30.64 | n/a |
| FY2023 | −$0.16 | −101% |
| FY2022 | $12.40 | −24% |
| FY2021 | $16.32 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$1.36 | n/a | −$15.41 | |
| Q1 FY26 | −$1.35 | n/a | −$17.82 | |
| Q4 FY25 | −$1.92 | n/a | −$16.66 | |
| Q3 FY25 | −$10.78 | n/a | −$17.38 | |
| Q2 FY25 | −$3.77 | n/a | −$6.90 | |
| Q1 FY25 | −$0.19 | n/a | −$5.33 | |
| Q4 FY24 | −$2.64 | −2740% | −$30.64 | |
| Q3 FY24 | −$0.30 | n/a | −$27.90 | |
| Q2 FY24 | −$2.20 | n/a | −$27.79 | |
| Q1 FY24 | −$25.50 | −3593% | −$26.39 | |
| Q4 FY23 | $0.10 | −78% | −$0.16 | |
| Q3 FY23 | −$0.19 | −168% | $0.19 |
Against its peers
Companies in Medical - Diagnostics & Research nearest QuidelOrtho's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| QDELQuidelOrtho | −$15.41 | |
| NRCNRC Health | $0.25 | −67% a year |
| CDNACareDx | $2.07 | +116% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| BLLNBillionToOne | $0.65 | |
| LNTHLantheus | $4.13 | +10% a year |
| CAICaris Life Sciences | $0.37 | |
| Peer median | $1.02 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on QuidelOrtho
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.